Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?
Investors are catching on to this rare gem among pharmaceutical stocks, but thanks to promising growth and a low valuation, further upside remains.
Royalty Pharma (NASDAQ: RPRX) offers investors a unique opportunity to gain exposure to both existing and future blockbuster drugs. This distinct approach positions the company between biotech stocks and traditional pharmaceutical companies, allowing for a diversified portfolio. Royalty Pharma operates as both a biopharma firm and a venture capital entity, investing in both established drug manufacturers and nonprofit researchers like universities.
In return for their financial support, the company receives a stake in the drugs they develop or are still in the research phase.
Despite the company's stock being priced at a relatively low valuation, the potential upside is considerable due to its ownership in 16 blockbuster drugs and a number of promising drug candidates. This combination of established and emerging opportunities suggests that Royalty Pharma may be a hidden gem within the healthcare sector, yet to receive the attention it deserves from market participants.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
